Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGPhase 4INTERVENTIONAL

Intrapleural Ropivacaine Infusion in Cardiac Surgery

Intrapleural Ropivacaine Infusion in Cardiac Surgery: Randomized Double-blind Controlled Study

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

For many patients, a primary source of postoperative pain following cardiac surgery is the presence of pleural drains, which the surgeon places at the end of the operation and maintains for 1 to 3 days. One promising method of pain management after cardiac surgery is interpleural analgesia, particularly when traditional analgesic methods, such as systemic opioids or epidural anesthesia, may be limited due to the risk of complications. Interpleural analgesia involves the introduction of local anesthetics directly into the pleural cavity through drainage tubes placed after cardiac surgery. This method targets pain receptors in the chest area, providing effective analgesia without significant systemic effects. Several clinical studies have confirmed the safety and efficacy of intrapleural administration of anesthetics after thoracic surgery. The aim of this randomised double-blind placebo controlled study is to test the hypothesis that, in patients after cardiac surgery, the quality of recovery from anesthesia with intrapleural use of ropivacaine is superior to that with a placebo.

Who May Be Eligible (Plain English)

Who May Qualify: - Scheduled cardiac surgery using a standard median sternotomy. - Planned opening of the pleural cavities. - Age more than 18 years. - Signed willing to sign a consent form to participate in the study. Who Should NOT Join This Trial: - Contraindications for ropivacaine - Redo surgery Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Scheduled cardiac surgery using a standard median sternotomy. * Planned opening of the pleural cavities. * Age more than 18 years. * Signed informed consent to participate in the study. Exclusion Criteria: * Contraindications for ropivacaine * Redo surgery

Treatments Being Tested

DRUG

Ropivacaine

The patient will receive 0.2% ropivacaine (20.0 ml) into the pleural cavity intraoperatively before sternal closure. A continuous infusion of 0.2% ropivacaine will be administered through a microcatheter into the drained pleural cavity, with titration of the infusion rate. The initial infusion rate is set at 10 ml/hour.

DRUG

0.9 % NaCl

The patient will receive 20.0 ml of a 0.9% sodium chloride solution into the pleural cavity intraoperatively, prior to sternal closure. A continuous infusion of 0.9% sodium chloride solution will then be administered through a microcatheter into the drained pleural cavity. The initial infusion rate is set at 10 ml/hour.

Locations (2)

Saint-Petersburg university hospital
Saint Petersburg, Russia
Primorskiy general hospital #1
Vladivostok, Russia